Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

Status unconfirmed · Phase 2/Phase 3

Conditions studied: Dry Age-related Macular Degeneration

In brief

This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.

Key facts

Study ID

NCT06229665

Run by

LumiThera, Inc.

People needed

75

Starts

2023-10-25

Expected to finish

2025-06-01

Last updated by the study team

2024-07-03

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Retina Vitreous Associates Medical Group — Beverly Hills, California, United States
• Stanford University — Palo Alto, California, United States
• Florida Eye Clinic — Altamonte Springs, Florida, United States
• Cumberland Valley Retina Consultants — Hagerstown, Maryland, United States
• New York Ear and Eye Infirmary — New York, New York, United States
• Gulf Coast Eye Institute — McAllen, Texas, United States
• Retina Center Northwest — Silverdale, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.